SynAct Pharma AB (STO:SYNACT)

Sweden flag Sweden · Delayed Price · Currency is SEK
21.00
-1.10 (-4.98%)
Aug 1, 2025, 5:29 PM CET
-4.98%
Market Cap1.11B
Revenue (ttm)n/a
Net Income (ttm)-82.18M
Shares Out50.01M
EPS (ttm)-1.92
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume171,308
Average Volume145,048
Open22.10
Previous Close22.10
Day's Range20.80 - 22.10
52-Week Range7.31 - 23.45
Beta1.00
RSI54.36
Earnings DateAug 20, 2025

About Despegar.com

SynAct Pharma AB, a clinical stage biotechnology company, researches and develops medicines for the treatment of inflammatory diseases in Sweden. The company develops AP1189, a drug candidate in Phase 2 clinical trial for the treatment of rheumatoid arthritis, idiopathic membranous nephropathy, and virus-induced respiratory insufficiency. It is also developing TXP-11, an advanced peptide agonist that is in preclinical trials for the prevention of organ failure in surgery; and various drug programs to treat auto-immune and inflammatory diseases.... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2012
Employees 6
Stock Exchange Nasdaq Stockholm
Ticker Symbol SYNACT
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.